You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of small near infrared laser system capable of improving immune responses to vaccines laser based adjuvant

    SBC: Veralase LLC            Topic: NIAID

    DESCRIPTION provided by applicant The lack of vaccine adjuvants that are both safe and effective is an important public health problem and is a key research priority for the NIH NIAID No adjuvants have yet been approved for use with intradermal vaccines The goal of this phase II STTR project is to move a new adjuvant for intradermal vaccination small near infrared lasers that emit brief non ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. IMMUNOLIPOSOME-MEDIATED GENE THERAPY FOR PROSTATE CANCER

    SBC: SYNERGENE THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Advanced prostate cancer tends to be relatively refractory to standard chemotherapeutic agents and radiation treatment, and this resistance correlates with a lack of functional p53. Our previous data indicate that cancer cells can be sensitized to radiation and chemotherapy via p53 replacement using a tumor-targeting liposomal delivery system. In the STTR Phase ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government